Damora Therapeutics Stock (NASDAQ:DMRA)

Financials Chart

Previous Close

$31.00

52W Range

$2.45 - $38.33

50D Avg

$26.91

200D Avg

$24.69

Market Cap

$1.89B

Avg Vol (3M)

$579.85K

Beta

1.47

Div Yield

-

DMRA Company Profile

Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Oct 29, 2020

Website

DMRA Performance

DMRA Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-210.87M	$-16.90M	$-36.46M
Net Income	$-209.84M	$-21.44M	$-38.35M
EBITDA	$-209.75M	$-21.22M	$-37.52M
Basic EPS	$-158.13	$-18.53	$-36.08
Diluted EPS	$-158.13	$-18.53	$-36.08

Fiscal year ends in Dec 25 | Currency in USD